Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (95)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (4)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Myeloma (293)
  5. Survivorship Research (212)
  6. Hematologic Malignancies Research (209)

More Groups

People
  1. Neha Korde (188)
  2. Alexander Lesokhin (167)
  3. Hani Hassoun (160)
  4. Sergio Giralt (158)
  5. Malin Hultcrantz (155)
  6. Heather Landau (144)

More People

Years
  1. 2025 (9)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (95)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. JAMA Oncology (12)
  5. Blood Cancer Journal (11)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (105)
  2. Elsevier Inc. (70)
  3. Nature Publishing Group (25)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The role of chimeric antigen receptor T-cell therapy in the era of bispecific antibodies
    Review

    Nath, K.; Mailankody, S.; Usmani, S. Z.
    Hematology/Oncology Clinics of North America (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial)
    Meeting Abstract

    Berdeja, J. G.; Martin, T. G.; Rossi, A.; Essell, J. H.; Siegel, D. S. D.; Mailankody, S.; Saini, N.; Holmes, H.; Dhakal, B.; Gasparetto, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM)
    Meeting Abstract

    Manasanch, E. E.; Korde, N.; Lee, H. C.; Patel, K. K.; Becnel, M.; Berrios, D.; Thomas, S. K.; Iyer, S. P.; Mailankody, S.; Amini, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Meeting Abstract

    Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations
    Journal Article

    Lipitz-Snyderman, A.; Chimonas, S.; Mailankody, S.; Kim, M.; Silva, N.; Kriplani, A.; Saltz, L. B.; Sihag, S.; Tan, C. R.; Widmar, M.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save
  • GPRC5D as a novel immunotherapeutic target in multiple myeloma
    Editorial

    Nath, K.; Costa, B. A.; Mailankody, S.
    Nature Reviews Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: A multi-institution experience
    Journal Article

    Kourelis, T.; Bansal, R.; Berdeja, J.; Siegel, D.; Patel, K.; Mailankody, S.; Htut, M.; Shah, N.; Wong, S. W.; Sidana, S.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results
    Journal Article

    Mailankody, S.; Matous, J. V.; Chhabra, S.; Liedtke, M.; Sidana, S.; Oluwole, O. O.; Malik, S.; Nath, R.; Anwer, F.; Cruz, J. C.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials
    Journal Article

    Cornetta, K.; Yao, J.; House, K.; Duffy, L.; Adusumilli, P. S.; Beyer, R.; Booth, C.; Brenner, M.; Curran, K.; Grilley, B.; more...
    Molecular Therapy (2023)

    Fulltext@MSK | Save